A controlled trial comparing dosimetry and radiation pneumonitis between tomotherapy and IMRT in patients with lung or esophageal cancer
Abstract
Backgroud: The expanding clinical use of helical tomotherapy (HT) has raised concerns regarding its potential to increase low-dose lung exposure and the risk of radiation pneumonitis (RP) in thoracic radiotherapy. While a few retrospective studies have compared dosimetric parameters and RP rates between HT and fixed-field intensity-modulated radiation therapy (IMRT), their findings remain inconsistent, necessitating a prospective randomized controlled trial for clarification.
Purpose: To prospectively compare dosimetric parameters and the incidence of RP between HT and IMRT in patients with lung or esophageal cancer.
Methods: Patients eligible for thoracic radiotherapy were enrolled. Both HT and IMRT plans were designed and optimized for each patient, with a prescription equivalent dose in 2 Gy /fraction (EQD2) ≥50 Gy to the gross tumor volume (GTV). Plans were evaluated based on target dose coverage, dose-volume histograms, and other dosimetric indices. RP was diagnosed and graded according to the Common Terminology Criteria for Adverse Events (version 5.0). Risk factors for RP were identified using univariate analysis.
Results: Between February and September 2022, 110 consecutive patients with lung or esophageal cancer were enrolled and randomly assigned in a 1:1 ratio to either the HT group (n = 54) or the IMRT group (n = 56). Compared with IMRT, HT had a significant reduction in lung V20 (p = 0.002) and mean lung dose (p = 0.013). Furthermore, the HT group exhibited a…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 56 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.